8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
May 1, 2026·SEC
Material company update
Feb 26, 2026·SEC
Lantheus Holdings, Inc.(LNTH)Earnings, Financials & Key Ratios
LNTH•NASDAQ
30.5× P/E·Price updated Jun 19, 2026
AboutLantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans; and Cobalt (Co 57), a non-pharmaceutical radiochemical; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz F 18 to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in pediatric and adults; PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. The company serves radio pharmacies, distributors, integrated delivery networks, hospitals, clinics, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; Curium; Bayer AG; CytoDyn Inc.; ROTOP; FUJIFILM; Regeneron Pharmaceuticals, Inc.; and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.Show more
- Revenue$1.54B+0.5%
- EBITDA$381M-27.0%
- Net Income$234M-25.2%
- EPS (Diluted)3.41-21.8%
- Gross Margin61.1%-5.2%
- EBITDA Margin24.71%-27.3%
- Operating Margin20.16%-32.3%
- Net Margin15.15%-25.6%
- ROE21.45%-34.6%
LNTH Key Insights
Lantheus Holdings, Inc. (LNTH) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Excellent 3Y average ROE of 35.3%
- ✓FCF machine: 23.0% free cash flow margin
- ✓Momentum leader: RS Rating 91 (top 9%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 35.3%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when LNTH posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
LNTH Price & Volume
Lantheus Holdings, Inc. (LNTH) stock price & volume — 10-year historical chart
Loading chart...
LNTH Growth Metrics
Lantheus Holdings, Inc. (LNTH) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years18.04%
5 Years35.35%
3 Years18.13%
TTM0.62%
Profit CAGR
10 Years-
5 Years-
3 Years102.64%
TTM9.72%
EPS CAGR
10 Years-
5 Years-
3 Years104.28%
TTM17.9%
Return on Capital
10 Years14.77%
5 Years14.1%
3 Years24.79%
Last Year17.11%
LNTH Recent Earnings
Lantheus Holdings, Inc. (LNTH) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 10/12 qtrs (83%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$1.46+16.8%
$1.25
Rev
$377M+6.4%
$354M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$1.67+41.5%
$1.18
Rev
$407M+10.8%
$367M
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$1.27+0.0%
$1.27
Rev
$384M+4.4%
$368M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$1.57-4.3%
$1.64
Rev
$378M+4.0%
$363M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.46vs $1.25+16.8% | $377Mvs $354M+6.4% |
| Q1 2026 | Feb 26, 2026 | $1.67vs $1.18+41.5% | $407Mvs $367M+10.8% |
| Q4 2025 | Nov 6, 2025 | $1.27vs $1.27+0.0% | $384Mvs $368M+4.4% |
| Q3 2025 | Aug 6, 2025 | $1.57vs $1.64-4.3% | $378Mvs $363M+4.0% |
Based on last 12 quarters of dataView full earnings history →
LNTH Peer Comparison
Lantheus Holdings, Inc. (LNTH) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RMD | 27.48B | 188.63 | 19.83 | 9.84% | 27.44% | 24.41% | 0.14 | |
 BWXT | 18.82B | 205.40 | 57.21 | 18.3% | 10.21% | 27.91% | 1.63 | |
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 ROIV | 22.61B | 31.43 | -73.09 | -71.57% | -36.29% | -6.03% | 0.02 | |
 GE | 373.67B | 357.64 | 43.83 | 18.48% | 17.91% | 45.85% | 1.08 | |
 GEHC | 28.02B | 61.59 | 13.54 | 4.84% | 7.54% | 14.45% | 0.94 | |
 MDT | 101.86B | 79.34 | 21.98 | 3.62% | 13% | 9.49% | 0.59 | |
 ISRG | 144.48B | 406.78 | 51.69 | 20.51% | 28.15% | 16.89% | 0.02 |
Compare LNTH vs Peers
Lantheus Holdings, Inc. (LNTH) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
LNTH Income Statement
Lantheus Holdings, Inc. (LNTH) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 331.38M | 343.37M | 347.34M | 339.41M | 425.21M | 935.06M | 1.3B | 1.53B | 1.54B | 1.55B |
Revenue Growth % | 9.78% | 3.62% | 1.15% | -2.28% | 25.28% | 119.91% | 38.65% | 18.32% | 0.5% | 0.62% |
Cost of Goods Sold | 169.24M | 168.49M | 172.53M | 200.65M | 237.51M | 353.36M | 586.89M | 545.62M | 599.66M | 611M |
COGS % of Revenue | 51.07% | 49.07% | 49.67% | 59.12% | 55.86% | 37.79% | 45.27% | 35.57% | 38.9% | - |
Gross Profit | 162.13M▲ 0% | 174.88M▲ 7.9% | 174.81M▼ 0.0% | 138.76M▼ 20.6% | 187.69M▲ 35.3% | 581.7M▲ 209.9% | 709.54M▲ 22.0% | 988.29M▲ 39.3% | 941.95M▼ 4.7% | 935.17M▲ 0% |
Gross Margin % | 48.93% | 50.93% | 50.33% | 40.88% | 44.14% | 62.21% | 54.73% | 64.43% | 61.1% | 60.48% |
Gross Profit Growth % | 17.68% | 7.86% | -0.04% | -20.62% | 35.27% | 209.92% | 21.98% | 39.29% | -4.69% | - |
Operating Expenses | 110.28M | 110.4M | 123.15M | 142.96M | 248.52M | 545.51M | 344.9M | 531.31M | 631.12M | 645.08M |
OpEx % of Revenue | 33.28% | 32.15% | 35.46% | 42.12% | 58.45% | 58.34% | 26.6% | 34.64% | 40.94% | - |
Selling, General & Admin | 92.16M | 93.33M | 103.13M | 110.17M | 218.82M | 233.83M | 267.19M | 371.63M | 453.81M | 464.71M |
SG&A % of Revenue | 27.81% | 27.18% | 29.69% | 32.46% | 51.46% | 25.01% | 20.61% | 24.23% | 29.44% | - |
Research & Development | 18.13M | 17.07M | 20.02M | 32.79M | 44.97M | 311.68M | 77.71M | 168.1M | 177.31M | 180.37M |
R&D % of Revenue | 5.47% | 4.97% | 5.76% | 9.66% | 10.58% | 33.33% | 5.99% | 10.96% | 11.5% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | -15.26M | 0 | 0 | -8.41M | 0 | 0 |
Operating Income | 51.85M▲ 0% | 64.49M▲ 24.4% | 51.66M▼ 19.9% | -4.2M▼ 108.1% | -60.83M▼ 1348.9% | 36.2M▲ 159.5% | 364.64M▲ 907.4% | 456.98M▲ 25.3% | 310.83M▼ 32.0% | 290.09M▲ 0% |
Operating Margin % | 15.65% | 18.78% | 14.87% | -1.24% | -14.3% | 3.87% | 28.13% | 29.79% | 20.16% | 18.76% |
Operating Income Growth % | -8.37% | 24.37% | -19.89% | -108.13% | -1348.9% | 159.51% | 907.44% | 25.32% | -31.98% | - |
EBITDA | 71M | 78.35M | 65.04M | 20.49M | -18.54M | 84.12M | 424.69M | 521.6M | 380.93M | 346.55M |
EBITDA Margin % | 21.42% | 22.82% | 18.73% | 6.04% | -4.36% | 9% | 32.76% | 34% | 24.71% | 22.41% |
EBITDA Growth % | -5.15% | 10.36% | -16.99% | -68.49% | -190.46% | 553.82% | 404.83% | 22.82% | -26.97% | -32.74% |
D&A (Non-Cash Add-back) | 19.14M | 13.86M | 13.38M | 24.69M | 42.29M | 47.93M | 60.04M | 64.62M | 70.1M | 56.46M |
EBIT | 58.05M | 66.95M | 42.24M | -2M | -67.29M | 33.9M | 430.96M | 450.65M | 333.54M | 313.53M |
Net Interest Income | -18.39M | -17.24M | -12.93M | -9.24M | -7.71M | -4.57M | -381K | 17.17M | -19.75M | -8.97M |
Interest Income | 18K | 167K | 686K | 238K | 45K | 2.61M | 19.64M | 36.84M | 0 | 10.84M |
Interest Expense | 18.41M | 17.41M | 13.62M | 9.48M | 7.75M | 7.18M | 20.02M | 19.67M | 19.75M | 19.81M |
Other Income/Expense | -12.21M | -14.94M | -23.03M | -7.28M | -14.21M | -9.48M | 46.3M | -26M | 2.96M | 83.58M |
Pretax Income | 39.64M▲ 0% | 49.55M▲ 25.0% | 28.63M▼ 42.2% | -11.48M▼ 140.1% | -75.04M▼ 553.7% | 26.72M▲ 135.6% | 410.94M▲ 1438.0% | 430.98M▲ 4.9% | 313.79M▼ 27.2% | 373.67M▲ 0% |
Pretax Margin % | 11.96% | 14.43% | 8.24% | -3.38% | -17.65% | 2.86% | 31.7% | 28.1% | 20.35% | 24.17% |
Income Tax | -83.75M | 9.03M | -3.04M | 1.99M | -3.76M | -1.35M | 84.28M | 118.53M | 80.23M | 94.64M |
Effective Tax Rate % | -211.27% | 18.22% | -10.62% | -17.37% | 5.01% | -5.05% | 20.51% | 27.5% | 25.57% | 25.33% |
Net Income | 123.39M▲ 0% | 40.52M▼ 67.2% | 31.67M▼ 21.8% | -13.47M▼ 142.5% | -71.28M▼ 429.1% | 28.07M▲ 139.4% | 326.66M▲ 1063.9% | 312.44M▼ 4.4% | 233.56M▼ 25.2% | 279.03M▲ 0% |
Net Margin % | 37.23% | 11.8% | 9.12% | -3.97% | -16.76% | 3% | 25.2% | 20.37% | 15.15% | 18.05% |
Net Income Growth % | 361.05% | -67.16% | -21.84% | -142.55% | -429.05% | 139.38% | 1063.86% | -4.35% | -25.25% | 9.72% |
Net Income (Continuing) | 123.39M | 40.52M | 31.67M | -13.47M | -71.28M | 28.07M | 326.66M | 312.44M | 233.56M | 279.03M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 3.17▲ 0% | 1.03▼ 67.5% | 0.79▼ 23.3% | -0.25▼ 131.6% | -1.06▼ 324.0% | 0.40▲ 137.7% | 4.65▲ 1062.5% | 4.36▼ 6.2% | 3.41▼ 21.8% | 4.24▲ 0% |
EPS Growth % | 286.59% | -67.51% | -23.3% | -131.65% | -324% | 137.74% | 1062.5% | -6.24% | -21.79% | 17.9% |
EPS (Basic) | 3.31 | 1.06 | 0.81 | -0.25 | -1.06 | 0.41 | 4.79 | 4.52 | 3.46 | - |
Diluted Shares Outstanding | 38.89M | 39.5M | 40.11M | 54.13M | 67.49M | 70.67M | 70.24M | 71.65M | 68.44M | 65.77M |
Basic Shares Outstanding | 37.28M | 38.23M | 38.99M | 54.13M | 67.49M | 68.49M | 68.27M | 69.2M | 67.49M | 64.74M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
LNTH Balance Sheet
Lantheus Holdings, Inc. (LNTH) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 147.85M | 195.41M | 172.91M | 184.22M | 235.79M | 677.62M | 1.09B | 1.33B | 899.96M | 942.29M |
Cash & Short-Term Investments | 76.29M | 113.4M | 92.92M | 79.61M | 98.51M | 415.65M | 713.66M | 912.81M | 359.12M | 498.58M |
Cash Only | 76.29M | 113.4M | 92.92M | 79.61M | 98.51M | 415.65M | 713.66M | 912.81M | 359.12M | 498.58M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 40.26M | 43.75M | 43.53M | 54M | 89.34M | 213.4M | 284.29M | 321.26M | 358.64M | 355.67M |
Days Sales Outstanding | 44.34 | 46.51 | 45.74 | 58.07 | 76.69 | 83.3 | 80.04 | 76.44 | 84.91 | 84.64 |
Inventory | 26.08M | 33.02M | 29.18M | 35.74M | 35.13M | 35.48M | 64.03M | 68.03M | 64.67M | 61.34M |
Days Inventory Outstanding | 56.25 | 71.53 | 61.73 | 65.02 | 53.98 | 36.64 | 39.82 | 45.51 | 39.37 | 37.37 |
Other Current Assets | 5.22M | 5.24M | 7.28M | 5.69M | 2.71M | 205K | 7.41M | 9.13M | 117.53M | 26.7M |
Total Non-Current Assets | 236.01M | 244.42M | 233.01M | 685.6M | 627.99M | 643.64M | 565.33M | 653.71M | 1.33B | 1.4B |
Property, Plant & Equipment | 93M | 107.89M | 116.5M | 138.61M | 125.56M | 141.2M | 192.02M | 212.88M | 163.69M | 157.56M |
Fixed Asset Turnover | 3.56x | 3.18x | 2.98x | 2.45x | 3.39x | 6.62x | 6.75x | 7.21x | 9.42x | 9.62x |
Goodwill | 15.71M | 15.71M | 15.71M | 58.63M | 61.19M | 61.19M | 61.19M | 61.19M | 239.52M | 239.4M |
Intangible Assets | 11.8M | 9.13M | 7.34M | 376.01M | 348.51M | 315.29M | 151.99M | 161.76M | 722.78M | 706.06M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 39.49M | 42.21M | 193.76M |
Other Non-Current Assets | 28.49M | 30.23M | 21.63M | 42.19M | 29.97M | 15.32M | 9.94M | 8.15M | 50.04M | 153.84M |
Total Assets | 383.86M▲ 0% | 439.83M▲ 14.6% | 405.92M▼ 7.7% | 869.82M▲ 114.3% | 863.78M▼ 0.7% | 1.32B▲ 53.0% | 1.65B▲ 25.0% | 1.98B▲ 19.9% | 2.23B▲ 12.5% | 2.35B▲ 0% |
Asset Turnover | 0.86x | 0.78x | 0.86x | 0.39x | 0.49x | 0.71x | 0.79x | 0.77x | 0.69x | 0.69x |
Asset Growth % | 50% | 14.58% | -7.71% | 114.28% | -0.69% | 52.96% | 24.97% | 19.94% | 12.48% | 46.8% |
Total Current Liabilities | 46.75M | 52.76M | 66.11M | 80.5M | 90.5M | 247.7M | 187.35M | 240.53M | 333.42M | 333.17M |
Accounts Payable | 17.46M | 17.95M | 18.61M | 16.28M | 20.79M | 20.56M | 41.19M | 34.56M | 42.91M | 45.88M |
Days Payables Outstanding | 37.66 | 38.9 | 39.37 | 29.62 | 31.94 | 21.24 | 25.62 | 23.12 | 26.12 | 29.27 |
Short-Term Debt | 2.75M | 2.75M | 10.14M | 20.7M | 11.64M | 354K | 823K | 974K | 738K | 803K |
Deferred Revenue (Current) | 23.79M | 30.01M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 12.07M | 16.09M | 17.05M | 25.59M | 28.08M | 155.65M | 48.24M | 60.25M | 289.77M | 286.49M |
Current Ratio | 3.16x | 3.70x | 2.62x | 2.29x | 2.61x | 2.74x | 5.80x | 5.52x | 2.70x | 2.83x |
Quick Ratio | 2.60x | 3.08x | 2.17x | 1.84x | 2.22x | 2.59x | 5.45x | 5.23x | 2.51x | 2.64x |
Cash Conversion Cycle | 62.93 | 79.14 | 68.11 | 93.47 | 98.73 | 98.7 | 94.25 | 98.83 | 98.16 | 92.74 |
Total Non-Current Liabilities | 313.82M | 316.07M | 225.21M | 275.11M | 308.85M | 626.41M | 647.91M | 651.8M | 804.18M | 801.13M |
Long-Term Debt | 265.39M | 263.71M | 183.93M | 197.7M | 163.12M | 557.71M | 561.67M | 565.28M | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 186K | 17.5M | 16.55M | 25.44M | 54.45M | 53.19M | 0 | 151.28M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 54.25M | 162.83M |
Other Non-Current Liabilities | 48.42M | 52.37M | 41.09M | 59.91M | 129.18M | 43.26M | 31.78M | 33.34M | 749.94M | 747.63M |
Total Liabilities | 360.57M | 368.83M | 291.32M | 355.62M | 399.35M | 874.11M | 835.26M | 892.33M | 1.14B | 1.13B |
Total Debt | 268.14M | 266.46M | 194.4M | 235.9M | 191.31M | 583.51M | 616.95M | 619.44M | 738K | 803K |
Net Debt | 191.85M | 153.06M | 101.48M | 156.29M | 92.8M | 167.86M | -96.71M | -293.38M | -358.38M | -497.78M |
Debt / Equity | 11.51x | 3.75x | 1.70x | 0.46x | 0.41x | 1.30x | 0.76x | 0.57x | 0.00x | 0.00x |
Debt / EBITDA | 3.78x | 3.40x | 2.99x | 11.51x | - | 6.94x | 1.45x | 1.19x | 0.00x | 0.00x |
Net Debt / EBITDA | 2.70x | 1.95x | 1.56x | 7.63x | - | 2.00x | -0.23x | -0.56x | -0.94x | -1.44x |
Interest Coverage | 3.15x | 3.85x | 3.10x | -0.21x | -8.68x | 4.72x | 21.53x | 22.91x | 16.89x | 15.83x |
Total Equity | 23.29M▲ 0% | 71M▲ 204.8% | 114.6M▲ 61.4% | 514.21M▲ 348.7% | 464.44M▼ 9.7% | 447.15M▼ 3.7% | 815.89M▲ 82.5% | 1.09B▲ 33.4% | 1.09B▲ 0.2% | 1.21B▲ 0% |
Equity Growth % | 121.87% | 204.85% | 61.41% | 348.69% | -9.68% | -3.72% | 82.47% | 33.35% | 0.16% | 12.81% |
Book Value per Share | 0.60 | 1.80 | 2.86 | 9.50 | 6.88 | 6.33 | 11.62 | 15.18 | 15.92 | 18.43 |
Total Shareholders' Equity | 23.29M | 71M | 114.6M | 514.21M | 464.44M | 447.15M | 815.89M | 1.09B | 1.09B | 1.21B |
Common Stock | 378K | 385K | 393K | 669K | 677K | 689K | 699K | 709K | 718K | 723K |
Retained Earnings | -209.01M | -168.14M | -136.47M | -149.95M | -221.22M | -193.16M | 133.5M | 445.94M | 679.5M | 797.92M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | -75M | -75M | -175M | 0 | 0 |
Accumulated OCI | -1.03M | -1.11M | -960K | -2.05M | -485K | -1.26M | -1.04M | -1.61M | -1.31M | -1.87M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
LNTH Cash Flow Statement
Lantheus Holdings, Inc. (LNTH) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 54.78M | 61.19M | 80.38M | 16.4M | 53.92M | 281.78M | 305.26M | 544.75M | 390.14M | 407.7M |
Operating CF Margin % | 16.53% | 17.82% | 23.14% | 4.83% | 12.68% | 30.14% | 23.55% | 35.51% | 25.31% | - |
Operating CF Growth % | 10.34% | 11.71% | 31.36% | -79.6% | 228.84% | 422.63% | 8.33% | 78.45% | -28.38% | -62.68% |
Net Income | 123.39M | 40.52M | 31.67M | -13.47M | -71.28M | 28.07M | 326.66M | 312.44M | 233.56M | 279.03M |
Depreciation & Amortization | 19.23M | 13.93M | 13.38M | 24.69M | 42.29M | 47.93M | 60.04M | 64.62M | 70.1M | 79.14M |
Stock-Based Compensation | 5.93M | 8.72M | 12.49M | 14.07M | 15.93M | 29.26M | 50.51M | 76.39M | 0 | 22.32M |
Deferred Taxes | -92.57M | 6.13M | 7.2M | -724K | 3.65M | -50.94M | -55.63M | -24.79M | 21.59M | 38.93M |
Other Non-Cash Items | 7.12M | 5.87M | 6.59M | 14.19M | 78.48M | 302.53M | 94.88M | 114.04M | 109.12M | -8.62M |
Working Capital Changes | -8.32M | -13.97M | 9.05M | -22.36M | -15.15M | -75.06M | -171.2M | 2.05M | -44.23M | -3.1M |
Change in Receivables | -3.41M | -3.98M | 156K | -7.46M | -33.1M | -128.46M | -68.64M | -37.69M | -17.89M | 6.24M |
Change in Inventory | -9.62M | -8.69M | 1.99M | -8.46M | -3.55M | -7.51M | -36.22M | -2.67M | -9.37M | -7.53M |
Change in Payables | 604K | -2.89M | 3.23M | -4.22M | 5.42M | 301K | 17.19M | -8.8M | -2.49M | -7.28M |
Cash from Investing | -16.31M | -19.13M | -22.06M | -4.91M | 3.68M | -276.55M | 5.94M | -226.01M | -627.17M | -537.46M |
Capital Expenditures | -17.54M | -20.13M | -22.06M | -12.47M | -12.14M | -18.35M | -46.55M | -79.63M | -41.5M | -41.42M |
CapEx % of Revenue | 5.29% | 5.86% | 6.35% | 3.68% | 2.86% | 1.96% | 3.59% | 5.19% | 2.69% | 2.68% |
Acquisitions | 1.23M | 1M | 0 | 17.56M | 0 | 0 | 0 | -80.91M | -575.67M | -496.45M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 1.23M | 1M | 0 | -10M | 15.82M | -258.2M | 52.49M | 17.77M | 0 | 5.41M |
Cash from Financing | -13.45M | -4.67M | -78.88M | -21.86M | -39.33M | 311.69M | -13.06M | -118.54M | -316.58M | -309.99M |
Debt Issued (Net) | -13.96M | -2.86M | -78.17M | -15.49M | -43.35M | 382.37M | -717K | -318K | -1.11M | -924K |
Equity Issued (Net) | 187K | 428K | 573K | 683K | 767K | -73.63M | 1.93M | -96.55M | -289.14M | -295.14M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | -75M | 0 | -100M | -300.02M | -300.02M |
Other Financing | 320K | -2.23M | -1.28M | -7.05M | 3.25M | 2.95M | -14.28M | -21.67M | -26.34M | -13.92M |
Net Change in Cash | 25.11M▲ 0% | 37.11M▲ 47.8% | -20.48M▼ 155.2% | -10.22M▲ 50.1% | 17.96M▲ 275.6% | 316.59M▲ 1663.0% | 298.04M▼ 5.9% | 199.2M▼ 33.2% | -553.66M▼ 377.9% | -439.94M▲ 0% |
Free Cash Flow | 37.23M▲ 0% | 41.06M▲ 10.3% | 58.32M▲ 42.0% | 3.92M▼ 93.3% | 41.78M▲ 965.2% | 263.43M▲ 530.6% | 258.7M▼ 1.8% | 493.13M▲ 90.6% | 354.05M▼ 28.2% | 371.69M▲ 0% |
FCF Margin % | 11.24% | 11.96% | 16.79% | 1.16% | 9.82% | 28.17% | 19.96% | 32.15% | 22.97% | 24.04% |
FCF Growth % | -11.86% | 10.28% | 42.04% | -93.28% | 965.17% | 530.59% | -1.8% | 90.61% | -28.2% | -21.03% |
FCF per Share | 0.96 | 1.04 | 1.45 | 0.07 | 0.62 | 3.73 | 3.68 | 6.88 | 5.17 | 5.65 |
FCF Conversion (FCF/Net Income) | 0.44x | 1.51x | 2.54x | -1.22x | -0.76x | 10.04x | 0.93x | 1.74x | 1.67x | 1.33x |
Interest Paid | 16.65M | 15.87M | 12.25M | 9.37M | 6.28M | 5.06M | 15.39M | 15.09M | 0 | 0 |
Taxes Paid | 106K | 90K | 12.25M | 340K | 215K | 54.05M | 151.58M | 153.81M | 0 | 0 |
LNTH Key Ratios
Lantheus Holdings, Inc. (LNTH) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 529.75% | 85.94% | 34.12% | -4.29% | -14.57% | 6.16% | 51.73% | 32.82% | 21.45% | 24.33% |
Return on Invested Capital (ROIC) | 23.18% | 22.02% | 17.61% | -0.71% | -7.43% | 4.63% | 41% | 45.28% | 30.55% | 19.08% |
Gross Margin | 48.93% | 50.93% | 50.33% | 40.88% | 44.14% | 62.21% | 54.73% | 64.43% | 61.1% | 60.48% |
Net Margin | 37.23% | 11.8% | 9.12% | -3.97% | -16.76% | 3% | 25.2% | 20.37% | 15.15% | 18.05% |
Debt / Equity | 11.51x | 3.75x | 1.70x | 0.46x | 0.41x | 1.30x | 0.76x | 0.57x | 0.00x | 0.00x |
Interest Coverage | 3.15x | 3.85x | 3.10x | -0.21x | -8.68x | 4.72x | 21.53x | 22.91x | 16.89x | 15.83x |
FCF Conversion | 0.44x | 1.51x | 2.54x | -1.22x | -0.76x | 10.04x | 0.93x | 1.74x | 1.67x | 1.33x |
Revenue Growth | 9.78% | 3.62% | 1.15% | -2.28% | 25.28% | 119.91% | 38.65% | 18.32% | 0.5% | 0.62% |
Related:LNTH Dividend History·LNTH Revenue History·LNTH Price History·LNTH P/E History·LNTH Financial Ratios·LNTH Institutional Holders
LNTH SEC Filings & Documents
Lantheus Holdings, Inc. (LNTH) SEC filings — annual & quarterly reports (10-K, 10-Q)
LNTH Frequently Asked Questions
Lantheus Holdings, Inc. (LNTH) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Lantheus Holdings, Inc. (LNTH) reported $1.55B in revenue for fiscal year 2025. This represents a 437% increase from $288.1M in 2012.
Lantheus Holdings, Inc. (LNTH) grew revenue by 0.5% over the past year. Growth has been modest.
Yes, Lantheus Holdings, Inc. (LNTH) is profitable, generating $279.0M in net income for fiscal year 2025 (15.2% net margin).
Dividend & Returns
Lantheus Holdings, Inc. (LNTH) has a return on equity (ROE) of 21.4%. This is excellent, indicating efficient use of shareholder capital.
Lantheus Holdings, Inc. (LNTH) generated $371.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.